{"id":"NCT02469090","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease","officialTitle":"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-18","primaryCompletion":"2017-12-11","completion":"2017-12-11","firstPosted":"2015-06-11","resultsPosted":"2020-07-30","lastUpdate":"2020-07-30"},"enrollment":141,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease, Off Episodes"],"interventions":[{"type":"DRUG","name":"APL-130277","otherNames":["Apomorphine Hydrochloride, Sublingual Thin Film"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"APL-130277","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations (\"OFF\" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.","primaryOutcome":{"measure":"Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part III) Score at Maintenance Visit 4 (MV4) - Week 12","timeFrame":"At t=0 (just prior to dosing) and t=30 minutes at MV4 (Week 12 of the Maintenance Treatment Phase).","effectByArm":[{"arm":"Placebo (Maintenance)","deltaMin":-3.5,"sd":1.29},{"arm":"APL-130277 (Maintenance)","deltaMin":-11.1,"sd":1.46}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":null},"locations":{"siteCount":33,"countries":["United States","Canada"]},"refs":{"pmids":["31818699"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":141},"commonTop":["Nausea","Somnolence","Dizziness","Yawning","Headache"]}}